Illinois Municipal Retirement Fund Sells 2,811 Shares of NeoGenomics, Inc. (NASDAQ:NEO)

Illinois Municipal Retirement Fund lowered its position in NeoGenomics, Inc. (NASDAQ:NEO) by 3.6% during the 4th quarter, Holdings Channel reports. The firm owned 75,265 shares of the medical research company’s stock after selling 2,811 shares during the quarter. Illinois Municipal Retirement Fund’s holdings in NeoGenomics were worth $1,218,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. BluePath Capital Management LLC bought a new stake in shares of NeoGenomics in the 3rd quarter valued at about $30,000. WINTON GROUP Ltd bought a new stake in NeoGenomics during the 3rd quarter valued at $133,000. Corton Capital Inc. purchased a new position in shares of NeoGenomics in the 3rd quarter valued at $141,000. Aigen Investment Management LP bought a new position in shares of NeoGenomics in the 3rd quarter worth $163,000. Finally, Mackenzie Financial Corp purchased a new stake in shares of NeoGenomics during the 3rd quarter worth $199,000. 98.50% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have issued reports on NEO shares. William Blair reiterated an “outperform” rating on shares of NeoGenomics in a research note on Wednesday, February 21st. Needham & Company LLC raised their target price on shares of NeoGenomics from $21.00 to $24.00 and gave the company a “buy” rating in a research note on Wednesday, February 21st. Piper Sandler upped their price target on NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Monday, February 26th. Finally, The Goldman Sachs Group raised their price objective on NeoGenomics from $17.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, February 22nd. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $19.50.

NeoGenomics Stock Up 2.1 %

NASDAQ:NEO opened at $14.14 on Friday. The company has a current ratio of 6.20, a quick ratio of 5.95 and a debt-to-equity ratio of 0.57. NeoGenomics, Inc. has a 12 month low of $11.03 and a 12 month high of $21.22. The firm has a fifty day simple moving average of $15.04 and a 200-day simple moving average of $15.92.

NeoGenomics (NASDAQ:NEO) last issued its quarterly earnings results on Tuesday, February 20th. The medical research company reported ($0.02) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The company had revenue of $155.55 million during the quarter, compared to analysts’ expectations of $152.90 million. NeoGenomics had a negative return on equity of 4.13% and a negative net margin of 14.87%. As a group, research analysts expect that NeoGenomics, Inc. will post -0.2 earnings per share for the current year.

Insider Activity at NeoGenomics

In other NeoGenomics news, General Counsel Alicia C. Olivo sold 2,587 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $14.96, for a total transaction of $38,701.52. Following the completion of the transaction, the general counsel now directly owns 34,866 shares of the company’s stock, valued at approximately $521,595.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 1.30% of the stock is owned by insiders.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.